Tumor stem cell niches: A new functional framework for the action of anticancer drugs

Recent Patents on Anti-Cancer Drug Discovery

Volumn 1, Issue 1, 2006, Pages 121-127

  Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cytokinetics; Cytotoxic drugs; Niche; Signal transduction inhibitors; Stem cells; Stroma; Survival factors; Vascular disrupting agents

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; CANCER STEM CELL; DRUG EFFECT; HUMAN; NEOPLASM; PATENT; PATHOLOGY; PHYSIOLOGY; REVIEW; STEM CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PATENTS AS TOPIC; STEM CELLS;

EID: 34250694387     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489206775246494     Document Type: Article

References (52)

1. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nature Rev Cancer 2005; 5(4): 311-21.
2. Watt FM, Hogan BL. Out of Eden: stem cells and their niches. Science 2000; 287(5457): 1427-30.
3. Gonzalez MA, Tachibana KE, Laskey RA, Coleman N. Control of DNA replication and its potential clinical exploitation. Nature Rev Cancer 2005; 5(2): 135-41.
4. Gregory CA, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: Molecular control of expansion and differentiation. Exp Cell Res 2005; 306(2): 330-335.
5. Brittan M, Wright NA. Gastrointestinal stem cells. J Pathol 2002; 197(4): 492-509.
6. Palma V, Lim DA, Dahmane N, et al. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development 2005; 132(2): 335-44.
7. Amoh Y, Li L, Katsuoka K, Penman S, Hoffman RM. Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons. Proc Natl Acad Sci USA 2005; 102(15): 5530-4.
8. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 2005; 307(5717): 1904-9.
9. Hamburger A, Salmon SE. Primary Bioassay of human tumor stem cells. Science 1977; 197: 461-3.
10. Houghton, J, Wang, TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterol 2005; 128(6): 1567-78.
11. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000; 60(14): 3689-95.
12. Watson JV. Tumour growth dynamics. Br Med Bull 1991; 47(1): 47-63.
13. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGFbeta in homeostasis and cancer. Nature Rev Cancer 2003; 3(11): 807-21.
14. Berezovskaya O, Schimmer AD, Glinskii AB, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 2005; 65(6): 2378-86.
15. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Rev Cancer 2005; 5(3): 172-83.
16. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435(7046): 1267-70-1270.
17. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nature Rev Cancer 2005; 5(4): 275-84.
18. Baguley BC, Marshall ES. In vitro modelling of human tumour behaviour in drug discovery programmes. Eur J Cancer 2004; 40(6): 794-801.
19. Basse B, Baguley BC, Marshall ES, et al. A mathematical model for analysis of the cell cycle in cell lines derived from human tumors. J Math Biol 2003; 47(4): 295-312.
20. Lahav G, Rosenfeld N, Sigal A, et al. Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 2004; 36(2): 147-50.
21. Finkel E. The mitochondrion: is it central to apoptosis? Science 2001; 292(5517): 624-6.
22. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408(6811): 433-9.
23. Rossi M, Sayan AE, Terrinoni A, Melino G, Knight RA. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann NY Acad Sci 2004; 1028: 143-9.
24. Yu J, Zhang L. No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 2003; 4(4): 248-9.
25. Vit JP, Rosselli F. Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene 2003; 22(54): 8645-52.
26. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE, Cabot MC. Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 2001; 47(5): 444-50.
27. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 22(20): 4217-26.
28. Zundel W, Giaccia A. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Development 1998; 12(13): 1941-6.
29. Bigelow RL, Chari NS, Unden AB, et al. Transcriptional regulation of Bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 2004; 279(2): 1197-205.
30. Hudziak, R.M., Shepard, H.M., Ullrich, A., Fendly, B.M.: US6399063B1 (2002).
31. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treatment 2005; 89 Suppl 1: S9-S15.
32. Bradbury, R.H., Kettle, J.G., McCabe, J., Turner, A.T., Hennequin, L.F.: US20050165035A1 (2005).
33. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005; 23(14): 3235-42.
34. Fletcher JA. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin Oncol 2004; 31(2 Suppl 6): 4-11.
35. Watkins DN, Peacock CD. Hedgehog signaling in foregut malignancy. Biochem Pharmacol 2004; 68(6): 1055-60.
36. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002; 297(5586): 1559-61.
37. Tas, S.: EP1561464A2 (2005).
38. Sanchez-Garcia I, Martin-Zanca D. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J Mol Biol 1997; 267(2): 225-8.
39. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23(14): 3227-34.
40. Baguley BC, Marshall ES, Holdaway KM, Rewcastle GW, Denny WA. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur J Cancer 1998; 34(7): 1086-90.
41. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nature Rev Cancer 2004; 4(6): 437-47.
42. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10(2): 145-7.
43. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30(3 Suppl 6): 39-50.
44. Baguley BC, Ching LM, Philpott M. Cancer treatment by combination therapy. New Zealand Patent Application 506,060 (2000).
45. Venit, J.J., Dali, M.V., Dali, M.M. et al.: EP1320534B1 (2005).
46. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nature Rev Cancer 2005; 5(6): 423-35.
47. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 2002; 86(12): 1937-42.
48. Read TA, Farhadi M, Bjerkvig R, et al. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 2001; 61(18): 6830-7.
49. Goldin A, Venditti JM, MacDonald JS, Muggia FM, Henney JE, DeVita VT, Jr. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 1981; 17(2): 129-42.
50. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83(11): 757-66.
51. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 1999; 29(9): 733-6.
52. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2(10): 727-39.